Pfizer announced that Chairman and CEO Albert Bourla will retire effective June 1, 2026, ending a tenure that saw the pharmaceutical giant rise to global prominence during the COVID-19 pandemic before facing a difficult transition in its aftermath. Chief Financial Officer David Denton will succeed Bourla as CEO.
A Legacy Defined by the Pandemic
Bourla joined Pfizer in 1993 and rose through the ranks, serving as chief operating officer before taking the helm as CEO in January 2019. Under his leadership, Pfizer partnered with BioNTech to develop one of the first authorized COVID-19 vaccines, a feat that generated tens of billions in revenue and elevated the company’s global profile.
Yet the post-pandemic years proved challenging. COVID-related revenues declined sharply, and Pfizer faced a looming patent cliff that threatened exclusivity on several blockbuster drugs beginning in 2026. Bourla responded with a pivot toward oncology, including the $43 billion acquisition of Seagen, and told Fortune in January 2026 that the company intended to “save the world from cancer” as its next mission.
Denton Takes the Reins
Denton, who joined Pfizer in 2022 after serving as CFO at Lowe’s, has been central to the company’s financial restructuring and cost-cutting efforts. On Pfizer’s Q1 2026 earnings call last week, Denton discussed the company’s strengthened cash position and $7 billion in deal-making capacity following a patent settlement on the cardiovascular drug Vyndamax.
Challenges Ahead
The leadership transition comes as Pfizer charts a path toward what Bourla described as “high single digit” annual revenue growth beginning in 2029. The company reported $14.5 billion in first-quarter 2026 revenue, representing 2% growth. The incoming CEO will need to navigate continued patent expirations, pipeline development, and an uncertain political environment around drug pricing and vaccine policy in the United States.
